BioCentury
ARTICLE | Company News

Stem Cell Therapeutics neurology news

July 5, 2010 7:00 AM UTC

Stem Cell terminated the employment contracts of its four senior officers and expects additional headcount reductions to cut costs after further analysis of the Phase IIb REGENESIS trial of NTx-265 to treat stroke did not show a "definitive explanation" for the large placebo effect. In May, the regimen of human chorionic gonadotropin (hCG) and epoetin alfa (EPO) for stimulation of innate stem cell proliferation in the brain missed the primary endpoint in the Phase IIb trial. Stem Cell plans to hold an end-of-Phase II meeting with FDA in October to discuss a Phase III trial of NTx-265 (see BioCentury, May 31).

CEO Alan Moore and CFO Barry Herring will remain as consultants for the next six months to assist the company in maximizing the value of its IP, including seeking partnerships. The company expects to eliminate or reduce additional staff positions and external research and service contracts.. ...